賽生藥業(06600.HK)香港發售股份獲1068倍認購 上限定價18.8港元/股
格隆匯 3 月 2日丨賽生藥業(06600.HK)發佈公吿，公司全球發售約1.16億股股份，其中香港發售股份5799.3萬股，國際發售股份5799.15萬股，另有15%超額配股權；發售價已釐定為每股發售股份18.80港元，每手買賣單位500股；摩根士丹利、中金公司及瑞信為聯席保薦人，預期股份將於2021年3月3日於聯交所主板掛牌上市。
國際發售項下初步提呈發售的發售股份已獲超額認購，相當於國際發售項下初步可供認購發售股份總數的約10.00倍。香港發售股份已獲非常大幅超額認購。已接獲合共436,000份根據香港公開發售提交的有效申請，認購合共123.88億股香港發售股份，相當於香港公開發售項下初步可供認購香港發售股份總數約1,068.05倍。
根據基石投資協議，基石投資者認購的發售股份數目現已釐定。(i)上藥國際供應鏈有限公司；(ii) Daguan International Limited；(iii)中郵創業國際資產管理有限公司；(iv) Ding Asset Ltd；(v) Bradbury Global Opportunity Fund SP；(vi)祥輝投資有限公司；(vii) IDG Capital Investment 2020 Limited；(viii)大眾(香港)國際有限公司；(ix)太平資產管理(香港)有限公司；(x)富喬鑫資本；及(xi)黃展雄各自已分別認購了1236.85萬股、1236.85萬股、824.55萬股、494.75萬股、412.75萬股、359萬股、206.1萬股、206.1萬股、206.2萬股、206.2萬股及123.65萬股，合計5513萬股發售股份，合共佔緊隨全球發售完成後公司已發行股本的約8.13%(假設超額配售權未獲行使)；及全球發售項下發售股份數目的約47.53%(假設超額配售權未獲行使)。
按發售價每股發售股份18.80港元計算，估計公司將收取的全球發售所得款項淨額約為20.395億港元(假設超額配售權未獲行使)。其中，約30.0%的所得款項淨額將用於投資中國或其他全球市場的潛在藥物收購目標併為新候選藥物的授權引入提供資金； 約28.0%將用於償還現有債務；約26.0%將用於為公司臨牀階段候選產品的開發及商業化提供資金，包括為RRx-001、Naxitamab、Omburtamab、PEN-866、PT112、ABTL-0812等產品的計劃臨牀試驗、註冊備案籌備及潛在商業發佈(包括銷售及營銷)提供資金；約10.0%將投入用於招聘、擴大銷售與營銷網絡以及商業及開發基礎設施，包括擴增公司的銷售團隊以籌備新產品上市及零售渠道合作，以及投資建立用於研發日達仙作為疫苗佐劑的適應症的疾控中心；及約6.0%將用於為公司的上市產品組合進行其他臨牀應用的持續臨牀研究提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
